Oral Care Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Oral Care Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Oral Care Market
The oral care market size was valued at USD 32.61 billion in 2023, and the market is now projected to grow from USD 33.63 billion in 2024 to USD 46.52 billion by 2032, exhibiting a CAGR of 4.14% during the forecast period of 2024-2032.
The production process of oral hygiene products is impacted by the significant worker movement from urban to rural regions. The rising cost of raw materials and the scarcity of vendor-supplied packaging materials were further challenges for producers. The COVID-19 pandemic and subsequent job losses and declining purchasing power of the worldwide populace have slowed down demand for these goods. A vast number of industries took a drastic forceful hit during the Covid period. These factors affected the oral care market growth.
Nowadays, the majority of dental illnesses that affect people are typical ones like tooth decay, oral cancer, and foul breath. Consumer demand for oral care products has increased as a result. A increasing number of dental offices and cosmetic stores, as well as increased consumer awareness of health and cleanliness, along with rising population income, are driving market expansion. These factors affected the oral care market share.
In order to address patients' additional personal care demands, a growing number of dentists now concentrate on providing basic oral caries and aesthetic spa services. This particular product market is driving and its revenue is off the charts because of this trend single handedly. The desire for associated dental cosmetic items may increase as a result of the patient experiencing less dental-related anxiety triggers throughout the procedure, including as visual, auditory, and olfactory stimuli.
Comprehensive Analysis of Oral Care Market
The market is divided into segments based on product type, including toothpaste, toothbrushes, mouthwash, and others. The market is split into residential and commercial segments based on application. The market is divided into hypermarkets/supermarkets, convenience stores, internet retailers, and other categories based on distribution.
Asia Pacific is expected to be the leading region of this particular product market and is anticipated to to grow over the forecasted period and also will continue to hold the largest market share.Because there are a lot of elderly people living in these countries, the Asia Pacific area has a dominant market. Tooth loss, dental decay, and gum disease are more common in the elderly population.
Moderate market fragmentation exists. In addition to spending money on R&D to manufacture items, these businesses have large production capacities. Colgate Palmolive Co. (U.S.), Unilever (U.K.), Procter & Gamble Co. (U.S.), Henkel AG & Co. KG aA (Germany), and Johnson & Johnson Services, Inc. (U.S.) are some of the major competitors of this particular product market.
In November 2021, The 100% recyclable plastic toothbrush handle was introduced by Colgate Palmolive. Transitioning to renewable energy with this launch will help lower the carbon footprint.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 4.14% from 2024 to 2032
Unit Value (USD Billion)
Segmentation By Product Type
Toothpaste
Toothbrush
Mouthwash
Others
By Application
Household
Commercial
By Distribution Channel
Hypermarket/Supermarket
Convenience Stores
Online Sales Channel
Others
North America (By Product Type, Application, Distribution Channel, and by Country)
The U.S. (By Product Type)
Canada (By Product Type)
Mexico (By Product Type)
Europe (By Product Type, Application, Distribution Channel, and by Country)
Germany (By Product Type)
France (By Product Type)
Italy (By Product Type)
Spain (By Product Type)
The U.K. (By Product Type)
Rest of Europe (By Product Type)
Asia Pacific (By Product Type, Application, Distribution Channel, and by Country)
China (By Product Type)
India (By Product Type)
Japan (By Product Type)
South Korea (By Product Type)
Australia (By Product Type)
Rest of Asia Pacific (By Product Type)
South America (By Product Type, Application, Distribution Channel, and by Country)
Brazil (By Product Type)
Argentina (By Product Type)
Rest of South America (By Product Type)
The Middle East and Africa (By Product Type, Application, Distribution Channel, and by Country)
South Africa (By Product Type)
UAE (By Product Type)
Saudi Arabia (By Product Type)
Rest of the Middle East and Africa (By Product Type)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
190 Pages
- 1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Cancer, By Region/Country, 2023
- 4.2. Overview of Different Oncology Drugs With Respect to Regulatory Approvals and Clinical Trials
- 4.3. Pricing Analysis, Key Brands / Key Players, 2023
- 4.4. Key Industry Development (Mergers, Acquisitions and Partnerships)
- 4.5. Impact of COVID-19 on the Market
- 5. Global Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Drug Class
- 5.1.1. Cytotoxic Drugs
- 5.1.1.1. Alkylating Agents
- 5.1.1.2. Antimetabolites
- 5.1.1.3. Others
- 5.1.2. Targeted Drugs
- 5.1.2.1. Monoclonal Antibodies
- 5.1.2.2. Others
- 5.1.3. Hormonal Drugs
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast – By Therapy
- 5.2.1. Chemotherapy
- 5.2.2. Targeted Therapy
- 5.2.3. Immunotherapy
- 5.3. Market Analysis, Insights and Forecast – By Indication
- 5.3.1. Lung Cancer
- 5.3.2. Stomach Cancer
- 5.3.3. Colorectal Cancer
- 5.3.4. Breast Cancer
- 5.3.5. Prostate Cancer
- 5.3.6. Others
- 5.4. Market Analysis, Insights and Forecast – By Dosage Form
- 5.4.1. Solid
- 5.4.1.1. Tablets
- 5.4.1.2. Capsules
- 5.4.2. Liquid
- 5.4.3. Injectable
- 5.4.3.1. Prefilled Syringes
- 5.4.3.2. Others
- 5.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies
- 5.5.3. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast – By Geography
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
- 6. North America Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Drug Class
- 6.1.1. Cytotoxic Drugs
- 6.1.1.1. Alkylating Agents
- 6.1.1.2. Antimetabolites
- 6.1.1.3. Others
- 6.1.2. Targeted Drugs
- 6.1.2.1. Monoclonal Antibodies
- 6.1.2.2. Others
- 6.1.3. Hormonal Drugs
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast – By Therapy
- 6.2.1. Chemotherapy
- 6.2.2. Targeted Therapy
- 6.2.3. Immunotherapy
- 6.3. Market Analysis, Insights and Forecast – By Indication
- 6.3.1. Lung Cancer
- 6.3.2. Stomach Cancer
- 6.3.3. Colorectal Cancer
- 6.3.4. Breast Cancer
- 6.3.5. Prostate Cancer
- 6.3.6. Others
- 6.4. Market Analysis, Insights and Forecast – By Dosage Form
- 6.4.1. Solid
- 6.4.1.1. Tablets
- 6.4.1.2. Capsules
- 6.4.2. Liquid
- 6.4.3. Injectable
- 6.4.3.1. Prefilled Syringes
- 6.4.3.2. Others
- 6.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies
- 6.5.3. Online Pharmacies
- 6.6. Market Analysis, Insights and Forecast – By Country
- 6.6.1. U.S.
- 6.6.1.1. By Drug Class
- 6.6.2. Canada
- 6.6.2.1. By Drug Class
- 7. Europe Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Drug Class
- 7.1.1. Cytotoxic Drugs
- 7.1.1.1. Alkylating Agents
- 7.1.1.2. Antimetabolites
- 7.1.1.3. Others
- 7.1.2. Targeted Drugs
- 7.1.2.1. Monoclonal Antibodies
- 7.1.2.2. Others
- 7.1.3. Hormonal Drugs
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast – By Therapy
- 7.2.1. Chemotherapy
- 7.2.2. Targeted Therapy
- 7.2.3. Immunotherapy
- 7.3. Market Analysis, Insights and Forecast – By Indication
- 7.3.1. Lung Cancer
- 7.3.2. Stomach Cancer
- 7.3.3. Colorectal Cancer
- 7.3.4. Breast Cancer
- 7.3.5. Prostate Cancer
- 7.3.6. Others
- 7.4. Market Analysis, Insights and Forecast – By Dosage Form
- 7.4.1. Solid
- 7.4.1.1. Tablets
- 7.4.1.2. Capsules
- 7.4.2. Liquid
- 7.4.3. Injectable
- 7.4.3.1. Prefilled Syringes
- 7.4.3.2. Others
- 7.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.6.1. U.K
- 7.6.1.1. By Drug Class
- 7.6.2. Germany
- 7.6.2.1. By Drug Class
- 7.6.3. France
- 7.6.3.1. By Drug Class
- 7.6.4. Spain
- 7.6.4.1. By Drug Class
- 7.6.5. Italy
- 7.6.5.1. By Drug Class
- 7.6.6. Scandinavia
- 7.6.6.1. By Drug Class
- 7.6.7. Rest of Europe
- 7.6.7.1. By Drug Class
- 8. Asia Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Drug Class
- 8.1.1. Cytotoxic Drugs
- 8.1.1.1. Alkylating Agents
- 8.1.1.2. Antimetabolites
- 8.1.1.3. Others
- 8.1.2. Targeted Drugs
- 8.1.2.1. Monoclonal Antibodies
- 8.1.2.2. Others
- 8.1.3. Hormonal Drugs
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast – By Therapy
- 8.2.1. Chemotherapy
- 8.2.2. Targeted Therapy
- 8.2.3. Immunotherapy
- 8.3. Market Analysis, Insights and Forecast – By Indication
- 8.3.1. Lung Cancer
- 8.3.2. Stomach Cancer
- 8.3.3. Colorectal Cancer
- 8.3.4. Breast Cancer
- 8.3.5. Prostate Cancer
- 8.3.6. Others
- 8.4. Market Analysis, Insights and Forecast – By Dosage Form
- 8.4.1. Solid
- 8.4.1.1. Tablets
- 8.4.1.2. Capsules
- 8.4.2. Liquid
- 8.4.3. Injectable
- 8.4.3.1. Prefilled Syringes
- 8.4.3.2. Others
- 8.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.6.1. Japan
- 8.6.1.1. By Drug Class
- 8.6.2. China
- 8.6.2.1. By Drug Class
- 8.6.3. India
- 8.6.3.1. By Drug Class
- 8.6.4. Australia
- 8.6.4.1. By Drug Class
- 8.6.5. Southeast Asia
- 8.6.5.1. By Drug Class
- 8.6.6. Rest of Asia Pacific
- 8.6.6.1. By Drug Class
- 9. Latin America Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Drug Class
- 9.1.1. Cytotoxic Drugs
- 9.1.1.1. Alkylating Agents
- 9.1.1.2. Antimetabolites
- 9.1.1.3. Others
- 9.1.2. Targeted Drugs
- 9.1.2.1. Monoclonal Antibodies
- 9.1.2.2. Others
- 9.1.3. Hormonal Drugs
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast – By Therapy
- 9.2.1. Chemotherapy
- 9.2.2. Targeted Therapy
- 9.2.3. Immunotherapy
- 9.3. Market Analysis, Insights and Forecast – By Indication
- 9.3.1. Lung Cancer
- 9.3.2. Stomach Cancer
- 9.3.3. Colorectal Cancer
- 9.3.4. Breast Cancer
- 9.3.5. Prostate Cancer
- 9.3.6. Others
- 9.4. Market Analysis, Insights and Forecast – By Dosage Form
- 9.4.1. Solid
- 9.4.1.1. Tablets
- 9.4.1.2. Capsules
- 9.4.2. Liquid
- 9.4.3. Injectable
- 9.4.3.1. Prefilled Syringes
- 9.4.3.2. Others
- 9.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.6.1. Brazil
- 9.6.1.1. By Drug Class
- 9.6.2. Mexico
- 9.6.2.1. By Drug Class
- 9.6.3. Rest of Latin America
- 9.6.3.1. By Drug Class
- 10. Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Drug Class
- 10.1.1. Cytotoxic Drugs
- 10.1.1.1. Alkylating Agents
- 10.1.1.2. Antimetabolites
- 10.1.1.3. Others
- 10.1.2. Targeted Drugs
- 10.1.2.1. Monoclonal Antibodies
- 10.1.2.2. Others
- 10.1.3. Hormonal Drugs
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast – By Therapy
- 10.2.1. Chemotherapy
- 10.2.2. Targeted Therapy
- 10.2.3. Immunotherapy
- 10.3. Market Analysis, Insights and Forecast – By Indication
- 10.3.1. Lung Cancer
- 10.3.2. Stomach Cancer
- 10.3.3. Colorectal Cancer
- 10.3.4. Breast Cancer
- 10.3.5. Prostate Cancer
- 10.3.6. Others
- 10.4. Market Analysis, Insights and Forecast – By Dosage Form
- 10.4.1. Solid
- 10.4.1.1. Tablets
- 10.4.1.2. Capsules
- 10.4.2. Liquid
- 10.4.3. Injectable
- 10.4.3.1. Prefilled Syringes
- 10.4.3.2. Others
- 10.5. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.6. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.6.1. GCC
- 10.6.1.1. By Drug Class
- 10.6.2. South Africa
- 10.6.2.1. By Drug Class
- 10.6.3. Rest of Middle East & Africa
- 10.6.3.1. By Drug Class
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. AbbVie, Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Novartis AG
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Pfizer Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Bristol Myers Squibb Company
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. GlaxoSmithKline plc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Eli Lilly and Company
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. AstraZeneca
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Sanofi
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Bayer AG
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Merck & Co., Inc.
- 11.2.11.1. Overview
- 11.2.11.2. Products & Services
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
